Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
G420030-2mg | 2mg | In stock | $42.90 | |
G420030-5mg | 5mg | In stock | $88.90 | |
G420030-10mg | 10mg | In stock | $147.90 | |
G420030-25mg | 25mg | In stock | $246.90 | |
G420030-50mg | 50mg | In stock | $444.90 | |
G420030-100mg | 100mg | In stock | $801.90 | |
G420030-200mg | 200mg | In stock | $1,441.90 |
Synonyms | Grapiprant|415903-37-6|CJ-023423|AAT-007|RQ-00000007|N-((4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide|CJ 023423|CJ-023|CJ-023,423|RQ-7|MR-10A7|UNII-J9F5ZPH7NB|J9F5ZPH7NB|MR10A7|Grapiprant (CJ-023423 |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of EP 4 receptor |
Product Description | Grapiprant (CJ-023,423, AT-001, AAT-007, RQ-00000007, CJ-23423) is a novel selective EP4 Prostaglandin Receptor inhibitor with Ki of 20 nM and 13 nM for rat EP4 receptor and human EP4 receptor, respectively. |
ALogP | 4.6 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea |
---|---|
INCHI | InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32) |
InChi Key | HZVLFTCYCLXTGV-UHFFFAOYSA-N |
Canonical SMILES | CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C |
Isomeric SMILES | CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C |
PubChem CID | 11677589 |
Molecular Weight | 491.61 |
PubChem CID | 11677589 |
---|---|
CAS Registry No. | 415903-37-6 |
ChEMBL Ligand | CHEMBL3039498 |
GPCRdb Ligand | grapiprant |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
C23081084 | Certificate of Analysis | Nov 23, 2022 | G420030 |
C23081131 | Certificate of Analysis | Nov 23, 2022 | G420030 |
C23081133 | Certificate of Analysis | Nov 23, 2022 | G420030 |
C23081136 | Certificate of Analysis | Nov 23, 2022 | G420030 |
C23081144 | Certificate of Analysis | Nov 23, 2022 | G420030 |
C23081147 | Certificate of Analysis | Nov 23, 2022 | G420030 |
C23081196 | Certificate of Analysis | Nov 23, 2022 | G420030 |
1. Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, Kato T, Okumura Y, Takada J. (2007) CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.. J Pharmacol Exp Ther, 322 (2): (686-94). [PMID:17495127] |